Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7059041 | 0.99 | TP53 (0.45) | TP53POLBHTTTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL8954138 | 0.91 | TP53 (0.43) | TP53POLBHTTTSHR | |
| SCHEMBL9272194 | 0.89 | TP53 (0.44) | TP53POLBHTTTSHR | |
| SCHEMBL7060199 | 0.88 | TP53 (0.57) | TP53POLBHTTALDH1A1HSD17B10 | |
| SCHEMBL8954122 | 0.86 | TP53 (0.48) | TP53POLBHTTALDH1A1HSD17B10 | |
| SCHEMBL7054174 | 0.84 | TP53 (0.48) | TP53 | |
| SCHEMBL9531817 | 0.84 | TP53 (0.42) | TP53POLBHTTTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL8954315 | 0.82 | TP53 (0.48) | TP53ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL8954062 | 0.82 | TP53 (0.47) | TP53 | |
| SCHEMBL8954114 | 0.82 | TP53 (0.47) | TP53ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0542872-A1 | HERBICIDAL SUBSTITUTED ARYL ALKYLSULFONYL PYRAZOLES | MONSANTO COMPANY (US) | 1993-05-26 | — | — | EP | claimed |
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| US-20020128300-A1 | Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.L.C. | 2002-09-12 | — | — | US | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010182-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010187-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010188-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992002510-A1 | SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992000068-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160985-A1 | Medicament | AGTR2, AGTR1, ACE | GAA 1525/4885TP53 3913/4885POLB 3530/4885 |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | GAA 529/4885TP53 4866/4885POLB 2857/4885 |
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | GAA 1338/4885TP53 3163/4885POLB 4596/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | GAA 2089/4885TP53 3514/4885POLB 2634/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | GAA 1268/4885TP53 3432/4885POLB 1951/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | GAA 1338/4885TP53 3163/4885POLB 4596/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | GAA 2568/4885TP53 3465/4885POLB 4518/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | GAA 1525/4885TP53 3913/4885POLB 3530/4885 |
| US-20020128300-A1 | Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, REN | GAA 847/4885TP53 4799/4885POLB 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.